Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2016 | The price of new innovation for the treatment of multiple myeloma

Eric Low • 12 Apr 2016
COMy 2016
Multiple Myeloma

Eric Low, Chief Executive of Myeloma UK, discusses recent advances in the development of new drugs for the treatment of patients with multiple myeloma and emphasises the importance of determining the cost effectiveness of new therapeutic approaches to ensure patient access.
Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

More from Eric Low

2:50
Why global collaborations are key in multiple myeloma
Eric Low • 28 Apr 2016
3:28
Improving strategies for executing successful clinical trials in multiple myeloma
Eric Low • 8 Jun 2016
1:41
Myeloma UK as a driver of collaboration between industry and academia
Eric Low • 7 Oct 2016
3:05
The rationale behind the Myeloma UK Clinical Trial Network
Eric Low • 7 Oct 2016

Related Videos

2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals